This allows your provider to personalize your plan and minimize the risk of interactions
de Araujo, M
In a separate study involving 190 patients receiving 52 weeks of treatment, remission rates were 36.8%, 45.6%, and 52.0% for the 5, 10, and 15 mg tirzepatide groups, respectively, compared to 18.2% in the placebo group (Loomba et al., 2024)
Ng, M., Emmanuela Gakidou, Lo, J., Abate, Y.H., Cristiana Abbafati, Abbas, N., Mohammadreza Abbasian, Samar Abd ElHafeez, Abdel-Rahman, W.M., Sherief Abd-Elsalam, Abdollahi, A., Meriem Abdoun, Abdulah, D.M., Rizwan Suliankatchi Abdulkader, Abdullahi, A., Abedi, A., Hansani Madushika Abeywickrama, Alemwork Abie, Aboagye, R.G
Separating Fact from Fiction on Safety Its completely normal to have questions about the safety of any new medical treatment